A Study of AL101 Monotherapy in Patients With Notch Activated Triple Negative Breast Cancer

NCT04461600 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

18

Enrollment

INDUSTRY

Sponsor class

Stopped Sponsor's decision

Conditions

Triple Negative Breast Cancer

Interventions

DRUG: AL101

Sponsor

Ayala Pharmaceuticals, Inc,